GET DAILY SIGNALSCalidi Biotherapeutics (CLDI) Stock Falls -25% Over 30 Days Amid Ongoing Financing Concerns
Key Takeaways
- Calidi Biotherapeutics (CLDI) shares fell roughly 25% over the trailing 30 days, extending a longer multi-month decline for the clinical-stage biotech.
- The stock has traded in a 52-week range of about $0.62 to $24.96, reflecting a deep drawdown as funding and dilution concerns intensified.
- Over the last quarter, CLDI declined approximately 57%, pressured by dilutive financing and an NYSE American stockholders' equity deficiency notice.
- Positive preclinical CLD-401 data presented at the ESMO 2026 Congress did not reverse the downward price trend.
- Persistent cash constraints and a reduced capital base remain central to investor sentiment around the stock.
Company Background and Pipeline Focus
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, specializing in immuno-oncology. It is advancing oncolytic virotherapies through its proprietary stem cell-based and enveloped platforms, notably NeuroNova and SuperNova technologies. These are intended to shield viruses from immune detection and direct them toward tumor sites.
The pipeline features CLD-101 (NeuroNova) for high-grade glioma, CLD-201 (SuperNova) for advanced solid tumors, and CLD-401 for metastatic solid tumors. The approach centers on an “off-the-shelf” delivery method for genetic medicines aimed at tumors irrespective of genetic makeup. As a pre-revenue company, it continues to rely on external capital.
Recent Stock Performance: 30-Day and Quarterly Moves
Over the past 30 days, CLDI shares moved from roughly $0.87 down to approximately $0.65, marking a decline of about 25%. The price action showed consistent downward pressure, with the stock printing new multi-month lows through late October and into November. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The quarterly picture looks steeper still. Starting from about $1.54, the shares dropped roughly 57% to current levels. This sustained slide has brought the price nearer its 52-week low around $0.62.
Factors Behind the 30-Day Decline
Positive preclinical data on CLD-401 was presented at the ESMO Congress 2026 in mid-October, showing tumor regression and complete responses in an EMT6 breast tumor model. Even so, the shares did not respond upward because financing and balance-sheet issues continued to weigh on sentiment.
An overhang remained from earlier capital raises and compliance matters. A $1.2 million registered direct offering completed in September contributed to dilution, while a late-September NYSE American notice on stockholders’ equity deficiency highlighted risks around listing status and overall financial position. Limited cash and ongoing losses kept the tone cautious.
Quarterly Drivers and Broader Context
The larger quarterly drop reflects the ongoing financial pressures typical for a pre-revenue biotech. Second-quarter 2026 results were released in August, and the company separately noted positive pre-IND feedback from the FDA for CLD-401, with first-patient dosing targeted for the first quarter of 2027. These clinical steps were overshadowed by balance-sheet concerns.
Share count rose materially from capital raises, and the NYSE American equity notice underscored the thin equity cushion. Ongoing cash burn, dilution, and listing-compliance risks dominated investor focus throughout the period.
Key Items to Monitor Going Forward
Attention will likely center on the next quarterly earnings release and any fresh updates on cash position given the continued need for financing. Progress toward the planned first-in-human study for CLD-401 remains an important milestone. Additional watchpoints include any new capital raises and their dilutive effects, efforts to address the NYSE American equity deficiency, and further clinical readouts from the NeuroNova and SuperNova platforms.
Using Tickeron AI Trading Bots for Market Context
In my own work, I occasionally reference Tickeron’s AI Trading Bots to help frame how automated strategies are behaving around names like this one. The platform hosts a wide selection of bots with varying timeframes and approaches, which can offer an additional lens when tracking volatile small-cap names amid sector-wide financing dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
CLDI's RSI Indicator climbs out of oversold territory
The RSI Oscillator for CLDI moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 32 of the 44 cases the stock moved higher. This puts the odds of a move higher at 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for CLDI just turned positive on October 30, 2026. Looking at past instances where CLDI's MACD turned positive, the stock continued to rise in 18 of 43 cases over the following month. The odds of a continued upward trend are 42%.
Following a +7.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDI advanced for three days, in 67 of 136 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.
CLDI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLDI as a result. In 58 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CLDI entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.577) is normal, around the industry mean (3.498). P/E Ratio (-0.019) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. CLDI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLDI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement